The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …

Inflammation response of epithelial mucosa to chemo-radiotherapy cytotoxic effects leads to
mucositis, a painful side effect of antineoplastic treatments. About 40% of the patients treated …

Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …

The identification of molecular targets and the growing knowledge of their cellular functions
have led to the development of small molecule inhibitors as a major therapeutic class for …

Biomarkers-guided precision therapeutics has revolutionized the clinical development and
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …